Trial Type: Lung Cancer

A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination with Anti-cancer Agents in Participants with Solid Tumors

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

A randomized phase 2 platform study of cemiplimab with chemotherapy versus cemiplimab with chemotherapy plus other cancer treatments for patients with resectable non-small cell lung cancer

ADC targeting EGFR and cMET (AZD9592) for metastatic colorectal cancer and EGFR mutated lung cancers that have progressed after standard therapy

JDQ443 for first-line treatment for KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.

Neoadjuvant ipilimumab and nivolumab with low dose SBRT fir resectable stage IB=III NSCLC. Closed to accrual. Open to biospecimen donation.

Bifunctional antibody against EGFR and TGF Beta, alone and in combination with pembrolizumab for Head and neck cancer, NSCLC and anal cancer and cutaneous squamous cell cancer